As expected, highly significant differences were observed between patients and controls in global cognitive status based on the PD-CRS [t(65) = 6.5; p < 0.0001], motor symptom severity based on the UHDRS-TMS [t(65) = 10.9; p < 0.0001], functional status based on the TFC [t(65) = 7.2; p < 0.0001], as well as on NfL plasma levels [t(65) = 10.73; p < 0.0001], all with large effect sizes (d > 0.8). The gene discussed is NEFL; the disease is Parkinson disease.